The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Apollon Formularies, Chief Executive Officer, Dr. , said: Stephen Barnhill
“We are delighted to be coming to market at such an important time for medical cannabis across the . The reaction to newly listed cannabis-related businesses has been remarkable, and we look forward to bringing Apollon, with its full suite of licences and THC inclusive formulations, to the market.UKLondon
“Apollon’s strong research and development ability will make us one of the few listed cannabis companies in that is able to treat patients with formulas inclusive of THC, and the licences held in mean that all our formulas are backed by medically supervised treatments. Our conditional fundraise of £2,500,000, as announced on 23 February, has shown a strong appetite for our company and we are pleased that we are able to provide the market with a truly unique investment opportunity.” EuropeJamaica
https://www.proactiveinvestors.co.uk/LON:AFRI/AfriAg-Global-plc/rns/950201
Wonder if we will join AIM
Global roll out and brand building.................... Stay tuned.............
https://pbs.twimg.com/media/Ew08fXhWEAAQc2v?format=jpg&name=medium
Apollon Formularies
@apollon_uk
Apollon’s strategy is to become a proven global medical company. Research & Development Licence allows drug discovery using THC and other cannabinoids.
so what does this mean, consolidation and ************** for current afriag holders? what are we getting based on what we currently have? same number shares just dilution and exchange?
David Lenigas
@DavidLenigas
Investegate |Afriag Global Plc Announcements | Afriag Global Plc: Notice of GM for Apollon Acquisition https://investegate.co.uk/afriag-global-plc/afri/notice-of-gm-for-apollon-acquisition/20210319070000PA0F5/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Afriag%20Global%20Plc%20Alert
Through its subsidiary in Jamaica, Apollon is licenced to develop, market, distribute and sell full spectrum (inclusive of THC) products in the legal medical cannabis markets, and will be one of the few listed companies in Europe that is able to do so.
Pleased to see it is finally happening, but LTH's have been well and truly taken to the cleaners. Pleased to see that none of the 'three musketeers', Lenigas, Strang or Harris are being retained, but no doubt they will have their outstanding salaries converted into placing or subscription shares.
Feeling very positive about the opportunity for Apollon and their unique offering against other Cannabis stocks who are restricted to CBD formulas.
Roll on the 12th April and with a fair wind, there could be a few more brokers offering online access to the Aquis platform by then.
Announcement today, papers being registered
Apollon Formularies
@apollon_uk
·
19m
Apollon has created and obtained proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Many of these formulations were created using Apollon’s proprietary artificial intelligence techniques.
https://twitter.com/apollon_uk
The major shareholders will be locked up for 12 months or more surely. Thats probably around 70% of the company.
This is THC as we all know, a major distinction, Im giving them 6 months to see what they can come up with
who says money doesn't grow on trees?
good luck all!
Just through Hl via phone.to be honest if it had been online I'd have probably sold them at a loss and moved on. I sold all the shares I could at profit and kept the rest, sat there five years.
I think we will get heavily diluted but still make a profit as potential is huge. Not long now, good to see and read of progress
blueblood Thanks for the update......... REC
Our shares are with HL............
Been asking H/L for online trading for AFRi for 3 years with no joy. Just checked today and still no go but hopefully in very near future!
David Lenigas
@DavidLenigas
·
2m
I heard from Aquis yesterday that Hargreaves Lansdown are already doing online trading on AQSE. Great for Upper Thames Plc.
@ValereumBlkchn
#UPPT
Apollon Formularies
@apollon_uk
·
13m
Will pot stock Canopy Growth benefit if cannabis gets legalized in New York?
Up 13 views.......
219 views now..........
https://www.youtube.com/watch?v=WrGqYDGOILA
Here mate save you searching............ We used to debate it..................
http://www.davidlenigas.com/
Andrew things here look brighter the news from Doc has helped for me........
We have both let steam off about Dave L and IMHO it is justified. Dave L once said share holders either love you or hate you depends on the share price.
Maybe Dave L wanted to move away from PDR who knows?
I must say that Doc is a breath of fresh air IMHO............
Andrew have a fresh read of Dave L's my two cent's worth............
Kenny, once we have a firm date for the RTO, I may even be tempted to add further to my holding if the share price stays at current levels. Think there is a good chance there could be a significant uplift from the current price range.
You never know....we may even get back to break-even on our individual holdings. Have to say this has been a long haul and I doubt I will pay any credence to anything DL says in the future.
It would be great if more brokers have allowed online trading by the time the RTO becomes effective. Can see a lot of interest given the publicity the company is receiving following their professional webcasts and PR.